Band-Aid, Tylenol Parent Tops Profit View, But Sales Fall A Bit Shy And Outlook Was Trimmed -- MarketWatch

Dow Jones11-07

Shares of Kenvue Inc. (KVUE) tacked on 0.5% in premarket trading Thursday, after the consumer health company, with brands including Band-Aid and Tylenol, topped third-quarter profit expectations and affirmed its full-year outlook. Net income fell to $383 million, or 20 cents a share, from $438 million, or 23 cents a share, in the same period a year ago. Excluding nonrecurring items, adjusted earnings per share of 28 cents was above the FactSet consensus of 27 cents. Net sales slipped 0.4% to $3.899, just why of the FactSet consensus of $3.920 billion, as a 1.6% decline in volume, driven by weakness in the skin health and beauty and self care business lines, offset a 2.5% increase in price and mix. For 2024, the company said it expects sales growth toward the low end of the previously provided guidance range of 1% to 3%, but still expects adjusted EPS of $1.10 to $1.20. The stock has gained 4.5% year to date through Wednesday, while the S&P 500 has run up 24.3%.

-Tomi Kilgore

For more from MarketWatch: http://www.marketwatch.com/newsviewer

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

November 07, 2024 06:57 ET (11:57 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481430970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481430970","market":"nz","top_or_hot":-1,"title":"Band-Aid, Tylenol Parent Tops Profit View, But Sales Fall A Bit Shy And Outlook Was Trimmed -- MarketWatch","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Shares of <a href=\"https://laohu8.com/S/KVUE\">Kenvue Inc</a>. (KVUE) tacked on 0.5% in premarket trading Thursday, after the consumer health company, with brands including Band-Aid and Tylenol, topped third-quarter profit expectations and affirmed its full-year outlook. Net income fell to $383 million, or 20 cents a share, from $438 million, or 23 cents a share, in the same period a year ago. Excluding nonrecurring items, adjusted earnings per share of 28 cents was above the FactSet consensus of 27 cents. Net sales slipped 0.4% to $3.899, just why of the FactSet consensus of $3.920 billion, as a 1.6% decline in volume, driven by weakness in the skin health and beauty and self care business lines, offset a 2.5% increase in price and mix. For 2024, the company said it expects sales growth toward the low end of the previously provided guidance range of 1% to 3%, but still expects adjusted EPS of $1.10 to $1.20. The stock has gained 4.5% year to date through Wednesday, while the S&amp;P 500  has run up 24.3%. \n</p>\n<p>\n     -Tomi Kilgore \n</p>\n<p>\n  For more from MarketWatch: http://www.marketwatch.com/newsviewer \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 07, 2024 06:57 ET (11:57 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Band-Aid, Tylenol Parent Tops Profit View, But Sales Fall A Bit Shy And Outlook Was Trimmed -- MarketWatch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBand-Aid, Tylenol Parent Tops Profit View, But Sales Fall A Bit Shy And Outlook Was Trimmed -- MarketWatch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Kenvue Inc. (KVUE) tacked on 0.5% in premarket trading Thursday, after the consumer health company, with brands including Band-Aid and Tylenol, topped third-quarter profit expectations and ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KVUE","symbol_name":"Kenvue Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481430970","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481430970","pubTimestamp":1730980620,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Kenvue Inc.  tacked on 0.5% in premarket trading Thursday, after the consumer health company, with brands including Band-Aid and Tylenol, topped third-quarter profit expectations and affirmed its full-year outlook. Net income fell to $383 million, or 20 cents a share, from $438 million, or 23 cents a share, in the same period a year ago. Excluding nonrecurring items, adjusted earnings per share of 28 cents was above the FactSet consensus of 27 cents. Net sales slipped 0.4% to $3.899, just why of the FactSet consensus of $3.920 billion, as a 1.6% decline in volume, driven by weakness in the skin health and beauty and self care business lines, offset a 2.5% increase in price and mix. For 2024, the company said it expects sales growth toward the low end of the previously provided guidance range of 1% to 3%, but still expects adjusted EPS of $1.10 to $1.20. The stock has gained 4.5% year to date through Wednesday, while the S&P 500  has run up 24.3%.This content was created by Ma","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KVUE":"Kenvue Inc"},"translate_title":"泰诺母公司创可贴利润预期最高，但销售额略有下降，前景也被下调——MarketWatch","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KVUE":0.9},"content_text":"Shares of Kenvue Inc. (KVUE) tacked on 0.5% in premarket trading Thursday, after the consumer health company, with brands including Band-Aid and Tylenol, topped third-quarter profit expectations and affirmed its full-year outlook. Net income fell to $383 million, or 20 cents a share, from $438 million, or 23 cents a share, in the same period a year ago. Excluding nonrecurring items, adjusted earnings per share of 28 cents was above the FactSet consensus of 27 cents. Net sales slipped 0.4% to $3.899, just why of the FactSet consensus of $3.920 billion, as a 1.6% decline in volume, driven by weakness in the skin health and beauty and self care business lines, offset a 2.5% increase in price and mix. For 2024, the company said it expects sales growth toward the low end of the previously provided guidance range of 1% to 3%, but still expects adjusted EPS of $1.10 to $1.20. The stock has gained 4.5% year to date through Wednesday, while the S&P 500  has run up 24.3%. \n\n\n     -Tomi Kilgore \n\n\n  For more from MarketWatch: http://www.marketwatch.com/newsviewer \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2024 06:57 ET (11:57 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481430970"}